Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10215677,clearance,"Complete restriction of kidney blood flow by bilateral suture-ligation of the renal arteries compared with sham-treated animals reduced the clearance of hBNP by approximately half (24 +/- 9 ml/min versus 47 +/- 14 ml/min, respectively, p <. 007).","Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215677/),[ml] / [min],24,32542,DB02557,Phosphoramidon
,10215677,clearance,"Complete restriction of kidney blood flow by bilateral suture-ligation of the renal arteries compared with sham-treated animals reduced the clearance of hBNP by approximately half (24 +/- 9 ml/min versus 47 +/- 14 ml/min, respectively, p <. 007).","Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215677/),[ml] / [min],47,32543,DB02557,Phosphoramidon
,2104235,plasma half-life,"The plasma half-life was approximately 2.5 min, and this was increased after nephrectomy, the kidney being the major organ through which the IL 1 alpha was excreted.",Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104235/),min,2.5,33211,DB02557,Phosphoramidon
,8032633,half-life,3. The half-life of neurotensin was estimated to be between 2 and 6 min.,"Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032633/),min,2 and 6,35901,DB02557,Phosphoramidon
,20388128,t(1/2),[(18)F]-big ET-1 was rapidly cleared from the circulation (t(1/2)= 2.9 +/- 0.1 min).,Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20388128/),min,2.9,99538,DB02557,Phosphoramidon
,20388128,t(1/2),"The ET(A) antagonist, FR139317 did not alter half-life of [(18)F]-big ET-1 (t(1/2)= 2.5 min) but radioactivity was reduced in all tissues except for kidney consistent with reduction in binding to ET(A) receptors.",Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20388128/),min,2.5,99539,DB02557,Phosphoramidon
,20388128,time to maximum accumulation,"In kidney, however, the peak in radioactivity was higher but time to maximum accumulation was slower ( approximately 30 min), which was increased by phosphoramidon, reflecting renal excretion with low conversion and binding to ET receptors.",Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20388128/),min,30,99540,DB02557,Phosphoramidon
